Quantcast

Latest UCB Stories

2011-05-10 09:00:00

BRUSSELS, May 10, 2011 /PRNewswire/ -- UCB announced today results from a post hoc analysis of the RAPID 1 study published in the Journal of Rheumatology. The results suggest moderate to severe rheumatoid arthritis (RA) patients treated with Cimzia® (certolizumab pegol), the only approved PEGylated anti-TNF, together with methotrexate (MTX), achieved a rapid response associated with improved long-term outcomes one year after treatment began. "These results are consistent...

2011-04-26 07:30:00

--Symposium Brings Together Industry, Investors, Scientific and Government Representatives to Advance Development of Drugs for Epilepsy-- MIDDLEBURG, Va., April 26, 2011 /PRNewswire-USNewswire/ -- The Epilepsy Therapy Project (ETP) today announced that a record number of emerging companies, industry executives, investors, scientific and government representatives will gather at the Antiepileptic Drug and Device Trials (AEDD) XI Conference to facilitate professional collaboration, funding...

2011-04-21 00:00:00

THOUSAND OAKS, Calif. and BRUSSELS, April 21, 2011 /PRNewswire/ -- Amgen (NASDAQ: AMGN) and UCB (Euronext Brussels: UCB) announced today positive top-line results from their Phase 2 clinical study comparing sclerostin-antibody AMG 785/CDP7851 to placebo in postmenopausal women with low bone mineral density (BMD) for the treatment of postmenopausal osteoporosis (PMO). This Phase 2 study met its primary endpoint, demonstrating significant increases in lumbar spine bone mineral density at...

2011-04-14 06:00:00

BRUSSELS, April 14, 2011 /PRNewswire/ -- New 5-year data from the longest prospective open-label Restless Legs Syndrome (RLS) study to date, show that Neupro® (rotigotine) demonstrated continued symptomatic clinical benefit with a low risk of augmentation. Over the five year period, clinically significant augmentation occurred in 5.1% of patients receiving rotigotine at EU approved doses (1, 2 and 3 mg/24h) and in 13.2% of patients receiving one of the five evaluated...

2011-04-13 12:30:00

BRUSSELS, April 13, 2011 /PRNewswire/ -- New rotigotine data shown in four poster presentations at the 63rd Annual Meeting of the American Academy of Neurology (AAN) in Hawaii, U.S., highlighted the importance in Parkinson's disease (PD) of addressing both motor- and non-motor symptoms, such as sleep. The data also demonstrated the long-term efficacy and tolerability of rotigotine and showed that plasma rotigotine levels remained stable following patch removal and application of a new...

2011-02-08 01:00:00

BRUSSELS and INCLINE VILLAGE, Nev., Feb. 8, 2011 /PRNewswire/ -- UCB SA (Euronext Brussels: UCB), on behalf of its affiliate UCB Pharma S.A. (UCB), and PDL BioPharma, Inc. (Nasdaq: PDLI) (PDL) today jointly announced that the companies have entered into a definitive settlement agreement that resolves all legal disputes between them, including those relating to UCB's pegylated humanized antibody fragment, Cimzia (certolizumab pegol), and PDL's patents known as the Queen et al. patents....

2011-01-12 11:15:00

ATLANTA, Jan. 12, 2011 /PRNewswire/ -- Comprehensive analyses of pooled data from three randomized, double-blind, placebo-controlled Phase II/III trials showing the efficacy and tolerability of Vimpat® (lacosamide) C-V for patients with partial-onset seizures, regardless of the type of concomitant AED used, have been published in the drug evaluation journal, CNS Drugs(1,2). Two key papers have reported that adjunctive lacosamide reduced seizures and improved responder...

2010-12-06 11:00:00

ATLANTA, Dec. 6, 2010 /PRNewswire/ -- UCB today announced new findings for Vimpat® (lacosamide) C-V that offer additional support regarding the long-term benefits of the antiepileptic drug (AED) as an adjunctive therapy for adults with uncontrolled partial-onset seizures. To view the multimedia assets associated with this release, please click: http://multivu.prnewswire.com/mnr/vimpat/34012/ "These data add to the growing body of support showing that...

2010-11-30 09:00:00

ATLANTA, Nov. 30, 2010 /PRNewswire/ -- New data on UCB's anti-epileptic drug (AED) Vimpat® (lacosamide) C-V will be presented at the 64th annual meeting of the American Epilepsy Society (AES), taking place at the San Antonio Convention Center in San Antonio, Texas from December 3 to 7. Data will also be presented on Keppra XR and the investigative epilepsy therapy, brivaracetam. Vimpat® tablets and injection were launched in the U.S. in May 2009 as an...

2010-11-22 11:03:00

ATLANTA, Nov. 22, 2010 /PRNewswire/ -- New stories and insights from the epilepsy community have been unveiled on EpilepsyAdvocate.com, including new interviews on "Women Succeeding with Epilepsy" and Epilepsy Advocate Radio. These programs represent UCB's continued commitment to the epilepsy community and seek to both empower patients and raise awareness about the condition. NEW WEBISODES FOR WOMEN! Two new video interviews are available featuring Epilepsy Advocates Amy Wyatt and...


Word of the Day
baudekin
  • A rich embroidered or brocaded silk fabric woven originally with a warp of gold thread.
'Baudekin' seems to be an alternative form of 'baldachin,' from the Italian 'Baldacco,' Baghdad, the city where the material was made.
Related